US lawmakers get ready to fight over Obamacare, again

27 March 2019

Most commercial executives in the industry thought the discussions over Obamacare were finally at an end, after a monthslong war of attrition between the White House and Congress early in Mr Trump’s presidency. They may need to think again.

The administration has thrown its weight behind a federal judge in Texas, who ruled that the entire Affordable Care Act should be discarded wholesale.

The court of appeals heard from Department of Justice lawyers that “the district court's judgment should be affirmed,” and that the US “is not urging that any portion of the district court's judgment be reversed."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK